EFFICACY AND SAFETY OF TRIAMCINOLONE ACETONIDE POSTERIOR SUBTENON INJECTION IN PATIENTS WITH DIABETIC MACULOPATHY
Abstract
Introduction
Diabetic maculopathy (DM) is the main cause of visual impairment of the working population. Optical coherence tomography and fluorescein angiography give us an precise insight into the retinal changes. In recent years pharmacological treatment of DM is increasing. Posterior subtenon application is accompanied by a smaller percentage of complications compared to intravitreal application.
Aim
The aim is to assess the efficacy and safety of triamcinolone acetonide (TA) posterior subtenon injection in the treatment of diabetic maculopathy by measuring intraocular pressure (IOP), central macular thickness (CMT) and visual acuity before and two months after.
Material and methods
The retrospective study included 49 patients admitted during 2016 for posterior subtenon injection of TA in the DM treatment at Daily Hospital for the treatment of vascular diseases of the eye and the macula Department of Ophthalmology, Clinical Center of Serbia. Data were collected from medical records on gender, age, type of retinopathy and visual acuity, IOP and CMT before and two months after intervention.
Results
The average age of patients was 63 ± 9.5 years, from 49 patients tested, 30.61% were female and 69.39 % were male. The frequency of NPDR in the study was 53.6%. There was a statistically significant difference in visual acuity and CMT before and two months after the intervention, but no correlation between improvement of visual acuity and CMT reduction. There wasn’t statistically significant difference in IOP before and two months after intervention.
Conclusion
The most common type of diabetic retinopathy in this study was NPDR. After posterior subtenon application of TA there was a significant increase in visual acuity and CMT reduction, but reduction of CMT isn’t connected with increase of visual acuity. Posterior subtenon TA application isn’t accompanied by a significant increase in IOP, and is an effective and relatively safe way of treating DM.
Keywords: Diabetic maculopathy, visual acuity, central macular thickness, intraocular pressure
References
Koleva-Georgieva DN, Sivkova NP. Types of diabetic macular edema assessed by optical coherence tomography. Folia Med (Plovdiv). 2008;50(3):30-8.
Institut za javno zdravlje Srbije ”Dr Milan Jovanović Batut”. Rezultati istraživanja zdravlja stanovništva Srbije 2013. godina. Beograd: Institut za javno zdravlje Srbije ”Dr Milan Jovanović Batut”;
Sicree R, Shaw JE, Zimmet PZ. The Global Burden of diabetes. In: Gan D, ed. Diabetes Atlas 4th ed. Brussels: International Diabetes Federation; 2015.
Romero-Aroca P. Targeting the pathophysiology of diabetic macular edema. Diabetes Care. 33. United States2010. p. 2484-5.
Warboys CM, Fraser PA. Hyperglycemia attenuates acute permeability response to advanced glycation end products in retinal microvasculature. Microvasc Res. 2010;80(1):174-6.
Pierce EA, Avery RL, Foley ED, Aiello LP, Smith LE. Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci U S A. 1995;92(3):905-9.
Romero-Aroca P, Baget-Bernaldiz M, Pareja-Rios A, Lopez-Galvez M, Navarro-Gil R, Verges R. Diabetic Macular Edema Pathophysiology: Vasogenic versus Inflammatory. J Diabetes Res. 2016;2016:2156273.
Cvetkovic D, Golubovic S, Ignjacev M et al. Oftalmologija za studente medicine. Beograd: Medicinski fakultet Univerziteta u Beogradu; 2016; 127-131.
Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol. 136. United States2003. p. 122-35.
Byeon SH, Chu YK, Hong YT, Kim M, Kang HM, Kwon OW. New insights into the pathoanatomy of diabetic macular edema: angiographic patterns and optical coherence tomography. Retina. 2012;32(6):1087-99.
Pearson PA, Comstock TL, Ip M et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: a 3-year multicenter, randomized, controlled clinical trial. Ophthalmology. 2011;118(8):1580-7.
Ozkiris A, Erkilic K. Complications of intravitreal injection of triamcinolone acetonide. Can J Ophthalmol. 2005;40(1):63-8.
Byun YS, Park YH. Complications and safety profile of posterior subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2009;25(2):159-62.
Ciulla TA, Walker JD, Fong DS, Criswell MH. Corticosteroids in posterior segment disease: an update on new delivery systems and new indications. Curr Opin Ophthalmol. 2004;15(3):211-20.
Gomez-Ulla F, Marticorena J, Alfaro DV, 3rd, Fernandez M, Mendez ER, Rothen M. Intravitreal triamcinolone for the treatment of diabetic macular edema. Curr Diabetes Rev. 2006;2(1):99-112.
Sue S. Test distance vision using a Snellen chart. Community Eye Health. 2007;20(63):52.
Grauslund J; Green A; Sjolie A. The Effect of Gender, Diabetic Retinopathy, Hypertension and
Javadzadeh A. The effect of posterior subtenon methylprednisolone acetate in the refractory diabetic macular edema: a prospective nonrandomized interventional case series. BMC Ophthalmol. 2006;6:15.
Ponto KA, Koenig J, Peto T et al. Prevalence of diabetic retinopathy in screening-detected diabetes mellitus: results from the Gutenberg Health Study (GHS). Diabetologia. 2016;59(9):1913-9.
Ohguro N, Okada AA, Tano Y. Trans-Tenon's retrobulbar triamcinolone infusion for diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2004;242(5):444-5.
Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. American Journal of Ophthalmology. 2005;139(2):290-4.
Toda J, Fukushima H, Kato S. Injection of triamcinolone acetonide into the posterior sub-tenon capsule for treatment of diabetic macular edema. Retina. 2007;27(6):764-9.
Ibraheem RF, Iqbal W. Role of posterior sub-tenon triamcinolone acetonide in patients of refractory macular oedema. J Pak Med Assoc. 2016;66(12):1602-5.
Nunes S, Pereira I, Santos A, Bernardes R, Cunha-Vaz J. Central retinal thickness measured with HD-OCT shows a weak correlation with visual acuity in eyes with CSME. Br J Ophthalmol. 2010;94(9):1201-4.
Kawamura R, Inoue M, Shinoda H, Shinoda K, Itoh Y, Ishida S, et al. Incidence of increased intraocular pressure after subtenon injection of triamcinolone acetonide. J Ocul Pharmacol Ther. 2011;27(3):299-304.